Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Hubei Biocause Heilen Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company specializing in the production of chemical raw materials and intermediates for the pharmaceutical industry. The company operates primarily in Hubei Province and has a competitive edge due to its low-cost production capabilities and a strong focus on R&D, which allows for the development of proprietary compounds.
The company generates revenue through the sale of chemical raw materials and intermediates used in pharmaceutical manufacturing. Its pricing power is supported by its low production costs and proprietary technologies, which enhance its product offerings and allow for tailored solutions to customers.
Changes in raw material prices, particularly for chemicals
Regulatory approvals for new pharmaceutical intermediates
Market demand for generic drugs in China
R&D breakthroughs leading to new product offerings
Regulatory changes in pharmaceutical manufacturing standards
Technological disruption in chemical production processes
Increased competition from domestic and international chemical manufacturers
Potential for price wars in the chemical raw materials market
Low return on equity and assets may indicate inefficiencies in capital utilization
Dependence on cash flow generation, which is currently negative
moderate - The company is somewhat sensitive to the economic cycle as pharmaceutical demand can fluctuate with consumer spending and healthcare budgets.
Interest rates impact the company's cost of capital for any potential expansion, though its current zero debt levels mitigate this risk. Higher rates could also affect customer purchasing power.
minimal - The company operates with no debt, reducing its exposure to credit conditions.
value - Investors may be attracted to the company's low debt levels and potential for recovery in margins.
moderate - The stock has shown significant price fluctuations, particularly with recent performance declines.
